Maze Reports Q1 Revenue of $20M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Should l Buy MAZE?
Reports Q1 revenue $20M, consensus $8.5M. License revenue was $20M for Q1. No license revenue was recognized for the quarter ended March 31, 2025. License revenue recognized in Q1 of 2026 reflects the achievement of a milestone pursuant to the exclusive license agreement with Shionogi & Co. for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup. Cash, cash equivalents and marketable securities were $362.9M as of March 31, compared to $360.0M as of December 31, 2025. Maze expects that its cash, cash equivalents and marketable securities as of March 31, together with the proceeds from the registered offering completed in April and a $20M milestone payment received from Shionogi & Co. in April, will fund operations into 2029 based on its current business plan.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MAZE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MAZE
Wall Street analysts forecast MAZE stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 25.520
Low
46.00
Averages
52.00
High
60.00
Current: 25.520
Low
46.00
Averages
52.00
High
60.00
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Maze Therapeutics Q1 Earnings Beat Expectations
- Earnings Highlights: Maze Therapeutics reported a Q1 GAAP EPS of -$0.45, beating expectations by $0.10, indicating an improvement in financial performance despite ongoing losses.
- License Revenue Surge: The company achieved $20 million in license revenue for Q1, exceeding market expectations by $11.5 million, suggesting increasing market acceptance and demand for its products.
- Stable Cash Reserves: As of March 31, 2026, Maze's cash, cash equivalents, and marketable securities totaled $362.9 million, a slight increase from $360.0 million on December 31, 2025, demonstrating solid financial management.
- Future Funding Outlook: Maze anticipates that its cash reserves, along with proceeds from the registered offering completed in April 2026 and a $20 million milestone payment from Shionogi & Co., Ltd., will fund operations into 2029, reflecting confidence in its future growth plans.
See More
Maze Therapeutics Executive Stock Transaction Overview
- Executive Stock Transaction: Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics, exercised and immediately sold 7,500 shares of common stock on April 29, 2026, for approximately $190,000, indicating a strategic liquidity management approach by the company's executives.
- Holding Changes: Dandekar's direct stock holdings were reduced by 41.66%, yet he retains 44,143 stock options, suggesting ongoing potential for equity exposure and continued interest in the company's future prospects.
- Transaction Context: This sale was executed under a Rule 10b5-1 trading plan, reflecting consistency with prior administrative transactions, and while the trade size has decreased, it still demonstrates Dandekar's confidence in the company's trajectory.
- Market Performance: Maze Therapeutics' stock has surged by 192% over the past year, closing at $25.68 on April 29, 2026, highlighting the company's strong growth potential in the biopharmaceutical sector.
See More
Maze Therapeutics Prices $150M Stock Offering
- Offering Size: Maze Therapeutics has priced its underwritten offering of 5.54 million shares at $23.50 each, along with pre-funded warrants for up to 850,000 shares at $23.499 each, aiming for gross proceeds of $150 million, which significantly bolsters its financial position.
- Use of Proceeds: The company intends to utilize the net proceeds primarily to advance research and development of its product candidates, as well as for general corporate purposes, which will enhance its ongoing innovation and competitiveness in the biopharmaceutical sector.
- Operational Funding Assurance: Maze expects that the net proceeds from this offering, combined with its current cash, cash equivalents, and marketable securities, will fund operations into 2029, ensuring the smooth execution of its R&D and market expansion plans over the coming years.
- Underwriting Arrangement: Leerink Partners is acting as the sole underwriter for the offering, which is expected to close around April 23, 2026, subject to customary closing conditions, reflecting the company's proactive approach in capital markets.
See More
Maze Therapeutics Raises $150 Million in Stock Offering
- Offering Size: Maze Therapeutics announced an underwritten offering of 5.54 million shares at $23.50 each and 850,000 pre-funded warrants, expected to raise approximately $150 million, indicating strong market confidence in its R&D projects.
- R&D Focus: The proceeds will primarily advance the development of MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease, highlighting the company's strategic emphasis on critical therapeutic areas.
- Funding Utilization: Maze expects that the net proceeds, combined with existing cash and marketable securities, will fund operations into 2029, ensuring its long-term R&D capabilities and market competitiveness.
- Market Reaction: Following the financing announcement, Maze Therapeutics' stock fell 4.28% to $25.69 on Nasdaq but rebounded 1.01% to $25.95 in after-hours trading, reflecting cautious optimism among investors regarding the company's future prospects.
See More
Maze Therapeutics Prices 5.54 Million Share Offering at $23.50 Each
- Offering Size: Maze Therapeutics announced the pricing of 5,540,000 shares at $23.50 each, expecting gross proceeds of $150 million, which reflects strong market confidence in its product development.
- Investor Participation: The offering attracted both new and existing investors, including Farallon Capital and T. Rowe Price, indicating market recognition of Maze's future potential and enhancing its financing capabilities in the biopharmaceutical sector.
- Use of Proceeds: Maze intends to use the proceeds primarily to advance the research and development of MZE829 and MZE782, targeting APOL1-mediated kidney disease and phenylketonuria, showcasing the company's strategic focus in therapeutic areas.
- Financial Outlook: Maze expects that the net proceeds from this offering will fund operations into 2029, reflecting a long-term plan in financial management and R&D investment, thereby boosting investor confidence in its sustainable growth.
See More
Maze Therapeutics Executive Sells Shares Amid Declining Stock Price
- Executive Stock Sale: Harold Bernstein, R&D President of Maze Therapeutics, sold 15,000 shares of common stock on April 1, 2026, for approximately $442,000, marking a complete exit from his direct holdings and indicating a strategic withdrawal from direct investment in the company.
- Options Exercise Context: The transaction was executed through the exercise of options, and Bernstein retains 237,407 outstanding stock options, suggesting he still has the potential to acquire shares in the future despite having no direct holdings.
- Market Reaction Analysis: Maze Therapeutics' stock price surged 208.05% over the past year, but after reaching a 52-week high of $53.65, the stock experienced a decline as investors began to cash in, which may correlate with Bernstein's sale.
- Investment Risk Advisory: While Bernstein's sale is not necessarily a negative signal as it was conducted under a Rule 10b5-1 trading plan, the company has yet to generate revenue and reported a net loss of $131.1 million in 2025, prompting investors to carefully assess the future approval prospects of its kidney drug, MZE829.
See More
Maze Therapeutics Q1 Earnings Beat Expectations
- Earnings Highlights: Maze Therapeutics reported a Q1 GAAP EPS of -$0.45, beating expectations by $0.10, indicating an improvement in financial performance despite ongoing losses.
- License Revenue Surge: The company achieved $20 million in license revenue for Q1, exceeding market expectations by $11.5 million, suggesting increasing market acceptance and demand for its products.
- Stable Cash Reserves: As of March 31, 2026, Maze's cash, cash equivalents, and marketable securities totaled $362.9 million, a slight increase from $360.0 million on December 31, 2025, demonstrating solid financial management.
- Future Funding Outlook: Maze anticipates that its cash reserves, along with proceeds from the registered offering completed in April 2026 and a $20 million milestone payment from Shionogi & Co., Ltd., will fund operations into 2029, reflecting confidence in its future growth plans.
See More
Maze Therapeutics Executive Stock Transaction Overview
- Executive Stock Transaction: Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics, exercised and immediately sold 7,500 shares of common stock on April 29, 2026, for approximately $190,000, indicating a strategic liquidity management approach by the company's executives.
- Holding Changes: Dandekar's direct stock holdings were reduced by 41.66%, yet he retains 44,143 stock options, suggesting ongoing potential for equity exposure and continued interest in the company's future prospects.
- Transaction Context: This sale was executed under a Rule 10b5-1 trading plan, reflecting consistency with prior administrative transactions, and while the trade size has decreased, it still demonstrates Dandekar's confidence in the company's trajectory.
- Market Performance: Maze Therapeutics' stock has surged by 192% over the past year, closing at $25.68 on April 29, 2026, highlighting the company's strong growth potential in the biopharmaceutical sector.
See More
Maze Therapeutics Prices $150M Stock Offering
- Offering Size: Maze Therapeutics has priced its underwritten offering of 5.54 million shares at $23.50 each, along with pre-funded warrants for up to 850,000 shares at $23.499 each, aiming for gross proceeds of $150 million, which significantly bolsters its financial position.
- Use of Proceeds: The company intends to utilize the net proceeds primarily to advance research and development of its product candidates, as well as for general corporate purposes, which will enhance its ongoing innovation and competitiveness in the biopharmaceutical sector.
- Operational Funding Assurance: Maze expects that the net proceeds from this offering, combined with its current cash, cash equivalents, and marketable securities, will fund operations into 2029, ensuring the smooth execution of its R&D and market expansion plans over the coming years.
- Underwriting Arrangement: Leerink Partners is acting as the sole underwriter for the offering, which is expected to close around April 23, 2026, subject to customary closing conditions, reflecting the company's proactive approach in capital markets.
See More
Maze Therapeutics Raises $150 Million in Stock Offering
- Offering Size: Maze Therapeutics announced an underwritten offering of 5.54 million shares at $23.50 each and 850,000 pre-funded warrants, expected to raise approximately $150 million, indicating strong market confidence in its R&D projects.
- R&D Focus: The proceeds will primarily advance the development of MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease, highlighting the company's strategic emphasis on critical therapeutic areas.
- Funding Utilization: Maze expects that the net proceeds, combined with existing cash and marketable securities, will fund operations into 2029, ensuring its long-term R&D capabilities and market competitiveness.
- Market Reaction: Following the financing announcement, Maze Therapeutics' stock fell 4.28% to $25.69 on Nasdaq but rebounded 1.01% to $25.95 in after-hours trading, reflecting cautious optimism among investors regarding the company's future prospects.
See More
Maze Therapeutics Prices 5.54 Million Share Offering at $23.50 Each
- Offering Size: Maze Therapeutics announced the pricing of 5,540,000 shares at $23.50 each, expecting gross proceeds of $150 million, which reflects strong market confidence in its product development.
- Investor Participation: The offering attracted both new and existing investors, including Farallon Capital and T. Rowe Price, indicating market recognition of Maze's future potential and enhancing its financing capabilities in the biopharmaceutical sector.
- Use of Proceeds: Maze intends to use the proceeds primarily to advance the research and development of MZE829 and MZE782, targeting APOL1-mediated kidney disease and phenylketonuria, showcasing the company's strategic focus in therapeutic areas.
- Financial Outlook: Maze expects that the net proceeds from this offering will fund operations into 2029, reflecting a long-term plan in financial management and R&D investment, thereby boosting investor confidence in its sustainable growth.
See More
Maze Therapeutics Executive Sells Shares Amid Declining Stock Price
- Executive Stock Sale: Harold Bernstein, R&D President of Maze Therapeutics, sold 15,000 shares of common stock on April 1, 2026, for approximately $442,000, marking a complete exit from his direct holdings and indicating a strategic withdrawal from direct investment in the company.
- Options Exercise Context: The transaction was executed through the exercise of options, and Bernstein retains 237,407 outstanding stock options, suggesting he still has the potential to acquire shares in the future despite having no direct holdings.
- Market Reaction Analysis: Maze Therapeutics' stock price surged 208.05% over the past year, but after reaching a 52-week high of $53.65, the stock experienced a decline as investors began to cash in, which may correlate with Bernstein's sale.
- Investment Risk Advisory: While Bernstein's sale is not necessarily a negative signal as it was conducted under a Rule 10b5-1 trading plan, the company has yet to generate revenue and reported a net loss of $131.1 million in 2025, prompting investors to carefully assess the future approval prospects of its kidney drug, MZE829.
See More
